Crowdonomics
Aeris Biotechnologies, Inc.

Reg A+ · Equity · Apr 2022

ClosedReg A+Equity
via DALMORE GROUP LLC · last checked Aug 16, 2026
Raised
$0 / $15M max
0% of ceiling
Investors
—
—
Estimated pre-money
$16.1M
—

Financials disclosed in this offering

FY2021 · hover for source
$0
FY2021
RevenueNet income
Metric
FY2021 audited
Income statement
Revenue
$0
Cost of goods sold
$0
Net income
$0
Balance sheet
Cash
$33,242
Accounts receivable
$0
Total assets
$33,242
Long-term debt
$50,000
Total liabilities
$104,548
Other
Headcount
2

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

3 amendments
  1. Jul 21, 2022
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  2. Jun 30, 2022
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  3. Jun 7, 2022
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$16.1M
Price / share$1.00
Shares offered15,000,000

Estimated, not stated: $1.00 × 16,080,500 securities outstanding.

Offering details

Target—
Max$15,000,000
Min investment—
OpenedApr 25, 2022
Deadline—
Days active1,629

Links & provenance

Source: SEC EDGAR
0001829126-22-008698
Last synced Aug 16, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.